# US 2012/0252038 A1 · Steroid receptor assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252038 A1
- Document ID: US20120252038A1
- Status: Published application
- Kind: A1
- Application number: 13/432,248
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Inventors: David A. Chianese
- Web page: https://patentgrep.com/patent/US20120252038A1

## CPC

- G01N 33/54326: {Magnetic particles}
- G01N 33/57515: of the breast
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/743: {Steroid hormones}
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/54: Determining the risk of relapse
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for the detection, enumeration and analysis of circulating tumor cells expressing steroid receptors, particularly estrogen receptors are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.

## Claims

### Claim 1

A method for characterizing circulating tumor cells from a patient with metastatic cancer, comprising the steps of:
a) obtaining a biological specimen(blood and bone marrow) from the patient;
b) contacting a the biological specimen is mixed with a ligand that reacts specifically with circulating tumor cells, to the substantial exclusion of other sample components, and permits the separation of such bound circulating tumor cells from other sample components of the biological specimen;
c) contacting the sample of step (b) with at least one reagent that specifically binds the samples of step (b);
d) contacting the sample of step (c) with an agent having binding affinity for steroid receptors in cells; and
e) analyzing the sample to determine the presence of circulating tumor cells expressing steroid receptors

### Claim 2 (depends on 1)

The method of claim 1, further comprising the step of determining the number of circulating tumor cells expressing the steroid receptors.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent that reacts specifically with circulating tumor cells is coupled to either or both N-terminal and C-terminal regions of said steroid receptors in said circulating tumor cells.

### Claim 4 (depends on 1)

The method of claim 1 wherein said reagent is selected from the group consisting of DAPI, cytokeratin and CD45 neg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ligand binds specifically to an epithelial cell adhesion epitope on the tumor cell.

### Claim 6 (depends on 1)

The method of claim 1 wherein the ligand comprises magnetically responsive particles.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample in step (e) is analyzed by at least one process selected from the group consisting of multiparameter flow cytometry, immunofluorescent microscopy, laser scanning cytometry, bright field base image analysis, spectral imaging analysis, manual cell analysis, CELLSTRACKS®analysis, and automated cell analysis.

### Claim 8 (depends on 6)

The method of claim 6 further comprising subjecting the product of step (b) to a magnetic field.

### Claim 9 (depends on 6)

The method of claim 6, wherein the magnetically responsive particles are colloidal.

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent is an antibody selected from the group consisting of ID5, CF11, E115 (rb mono), ER119.3, and SP-1 (rb mono).

### Claim 11 (depends on 1)

The method of claim 1 wherein the agent is an antibody selected from the group consisting of H222, F10, and TE111.5D11

### Claim 12

A test kit for screening a patient sample for the presence of circulating tumor cells expressing a steroid receptor comprising:
a) a ligand that reacts specifically with circulating tumor cells, to the substantial exclusion of other sample components, and permits the separation of such bound circulating tumor cells from other sample components of the biological specimen;
b) at least one reagent that specifically binds either or both circulating tumor cells and other sample components of a patient
c) an agent having binding affinity for steroid receptors in the circulating tumor cells of the patient.
